Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial

Abstract Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib is an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor tyrosine kinase associated with poor prognosis, chemothera...

Full description

Bibliographic Details

Published in:	Nature Communications
Main Authors:	Sonja Loges, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto Lemoli, Daniele Mattei, Walter Fiedler, Yesid Alvarado-Valero, Isabel Ben-Batalla, Jonas Waizenegger, Lisa-Marie Rieckmann, Melanie Janning, Maike Collienne, Charles D. Imbusch, Niklas Beumer, David Micklem, Linn H Nilsson, Noëlly Madeleine, Nigel McCracken, Cristina Oliva, Claudia Gorcea-Carson, Bjørn T. Gjertsen
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-03-01
Online Access:	https://doi.org/10.1038/s41467-025-58179-6